Product Description
Aldoxorubicin is a prodrug of doxorubicin that binds to serum albumin immediately after administration through an acid-sensitive hydrazone linker and is subsequently transported to tumor tissues where the acidic environment cleaves the linker and facilitates delivery of a tumor-targeted drug payload. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896668/)
Mechanisms of Action: Serum Albumin Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ImmunityBio
Company Location: SAN DIEGO CA 92121
Company CEO: Richard Adcock
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Sarcoma
Phase 2: Hepatocellular Carcinoma|Glioblastoma|Chordoma|Triple Negative Breast Cancer|Small Cell Lung Cancer|Sarcoma|Pancreatic Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|HIV Seropositivity|Pancreatic Ductal Carcinoma|Sarcoma, Kaposi|Adenocarcinoma
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| QUILT-3.067 | P2 |
Terminated |
Triple Negative Breast Cancer |
2020-09-11 |
|
| QUILT-3.091 | P2 |
Withdrawn |
Chordoma |
2020-08-31 |
|
| TNBC | P2 |
Withdrawn |
Triple Negative Breast Cancer |
2020-06-01 |
|
| QUILT-3.088 | P2 |
Withdrawn |
Pancreatic Cancer |
2019-12-30 |